Janux Therapeutics has dosed the first participant in a Phase I clinical trial of JANX011, a Cluster of Differentiation 19 ...

Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end ...

By Hugo Francisco de Souza A novel nasal booster approach may help close the gap between systemic vaccination and infection-blocking mucosal immunity, offering fresh insight into next-generation COVID ...

We are now approaching six years since COVID-19 was declared a pandemic by the World Health Organization, yet talk of ...

Myasthenia Gravis (MG) is a rare autoimmune disease in which the immune system attacks the connection between nerves and muscles. This attack causes ...

Constant exposure to diverse diseases is an occupational hazard for all healthcare workers, especially those who work with children. | Constant exposure to diverse diseases is an occupational hazard ...

A new study shows that targeting key epigenetic proteins may permanently switch off cancer genes. Scientists at Monash University, working with Harvard University, report they have found a way to ...

The Epstein-Barr virus (EBV) can cause certain types of cancer or autoimmune diseases, but how the body controls this common viral infection is largely unknown. Researchers at the University Hospital ...

A research team led by scientists at Queen Mary University of London and University College London (UCL) has found new clues about how the brains of people with Down syndrome develop differently from ...

ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countries -- Dublin-based subsidiary to support ImmunityBio's distribution and ...

Myasthenia Gravis (MG) is a rare autoimmune disease in which the immune system attacks the connection between nerves and ...

Researchers have identified a specific liver protein produced during exercise that strengthens the brain’s protective barrier ...